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Randomized Controlled Trials (RCTs) are the “gold standard” for evaluating treatment outcomes
providing information on treatments “efﬁcacy”. They are designed to test a therapeutic hypothesis under
optimal setting in the absence of confounding factors. For this reason they have high internal validity.
The strict and controlled conditions in which they are conducted, leads to low generalizability because
they are performed in conditions very different from real life usual care. Conversely, real life studies
inform on the “effectiveness” of a treatment, that is, the measure of the extent to which an intervention
does what is intended to do in routine circumstances. At variance to RCTs, real life trials have high
generalizability, but low internal validity. Recently the number of real life studies has been rapidly
growing in different areas of respiratory medicine, particularly in asthma and COPD. The role of such
studies is becoming a hot topic in respiratory medicine, attracting research interest and debate.
In the ﬁrst part of this review we discuss some of the advantages and disadvantages of different types
of RCTs and analyze the strengths and weaknesses of real life trials, considering the recent examples of
some studies conducted in COPD. We then discuss methodological approaches and options to overcome
some of the limitations of real life studies.
Comparing the conclusions of effectiveness and efﬁcacy trials can provide important pieces of infor-
mation. Indeed, these approaches can result complementary, and they can guide the interpretation of
each other results.
 2014 Elsevier Ltd. All rights reserved.1. Introduction
Research evolves by answering new questions, including ques-
tions on how research itself should be conducted. Randomized
Controlled Trials (RCTs) are well recognized as the “gold standard”
for evaluating treatment outcomes [1,2]. They are designed to test as; COPD, chronic obstructive
onia; CF, cystic ﬁbrosis; ITT,
MDIs, breath-actuated pres-
nhalers; pMDIs, pressurized
t; LTRA, leukotriene receptor
dicine, University of Ferrara,
236908.
.it (A. Papi).
All rights reserved.therapeutic hypothesis under optimal conditions in the absence of
confounding factors: highly selected patients, optimal manage-
ment conditions, and ideal settings; thus they provide information
on “efﬁcacy” under conditions very different from real life [3,4].
They accomplish this through an experimental design [2,5,6] that,
as their name implies, always includes randomization to guarantee
that treatment groups are as similar as possible in all attributes that
could potentially inﬂuence outcomes [2,5]. Thus, RCTs have high
internal validity under the ideal conditions in which they are
conducted [1,2]. Concerns about the conclusions of RCTs relate
mainly to their generalizability to broader patient populations and
to less ideal conditions, like routine clinical practice, where even
health care costs and availability can be problematic [2]. Indeed, it
is argued that, because of statistical need of limiting confounding
factors, the highly selected population of RCTs only partially
Table 1
Advantages and disadvantages of RCTs and real life studies.
RCTs Real life studies
Advantages  Rigorous experimental
design
 Non-selected population
 Refer to the usual
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validity of these clinical trials. Assessment of outcomes under these
sub-optimal conditions in observational or pragmatic studies in-
forms on the “effectiveness” of a treatment in real life [3,4], that is,
the measure of the extent to which an intervention does what is
intended to do in routine circumstances.
Observational studies have the power and structure to identify
areas in which investigation is needed and to test new hypotheses
[7]. Pragmatic trials are designed to evaluate treatment outcomes,
but unlike RCTs they adopt usual care settings and procedures in
non-selected patients [7], thus mimicking everyday clinical prac-
tice, which provides high external validity. Real life studies have
limitations, primarily stemming from the lack of randomization
and the need to apply the indications only within the local
geographic context.
In the ﬁrst part of this review, we will mainly refer to real life
studies conducted in asthma, where they have a long history, as
documented by the large number published in the last 10 years.
Recently the number of real life studies in pharmacological has
been rapidly growing in other areas of respiratory medicine,
particularly chronic obstructive pulmonary disease (COPD) (Fig. 1).
During the same period the overall number of RCTs in asthma and
COPD was several times higher and tended to be constant over
time: there were on average more than 400 RCTs every year on
asthma (5%) and more than 200 RCTs/year on COPD (8%).
The progressive increase of real life studies published in the last
years and their recognized scientiﬁc value [8,9] underline that their
role is becoming constructive in respiratory medicine, attracting
research interest and debate [10,11]. The second part of the review
will consider some of the advantages and disadvantages, strengths
and weaknesses of different types of trials and comment on the
complementarity between RCTs and real life studies.
2. Randomised Controlled Trials
2.1. RCTs: deﬁnition and features
RCTs are research studies that aim to evaluate treatment efﬁcacy
[12].
Evidence-based clinical trials start from the formulation of a
research hypothesis [13], which may be an evaluation of “superi-
ority” or “equivalence” [13]. The appropriate primary outcome and
corresponding measuring tool are chosen [13] and the number ofFig. 1. Real life studies in asthma and/or COPD in the last decade. PubMed search:
Percent variations in the last decade of published studies on asthma and/or COPD
containing the term “real-life” in the title or abstract.patients is estimated based on statistical parameters, historical data
on the working hypotheses, clinically relevant differences and the
inherent variability of the primary outcomes.
Random assignment to treatment groups and double blind
monitoring minimize bias [13].
The effect of the tested treatment is assessed by comparing it to
a control condition, standard treatment or placebo [13]. Different
treatment strategies or dosages can also be compared. These
criteria maximize internal validity but at the same time, limit
generalizability and reduce external validity [14].2.2. RCTs: advantages
Because of their internal strength, RCTs are universally accepted
as the “gold standard” for assessing the effects of therapeutic in-
terventions and of medical devices/equipment under speciﬁc
controlled conditions [7,15e19].
Historically, the ﬁrst RCTs available in the respiratory literature
addressed community acquired pneumonia (CAP), but they did not
follow all of the strict RCT rules. A critical assessment of the early
studies revealed design ﬂaws: the diagnosis of pneumonia was not
deﬁned in 42.8% of the RCTs, only 33% of the studies were restricted
to CAP, and outcomes were not deﬁned in 28.5% of the studies [20].
Moreover, only 38% of the RCTs were double-blinded, and intention
to treat analysis was not applied [20]. During the ensuing years,
signiﬁcant improvements were made in all methodological aspects
of RCTs in respiratory medicine. One of the most recent published
RCT on respiratory infections [21] evaluated macrolide mainte-
nance treatment with azithromycin in adults with bronchiectasis
not due to cystic ﬁbrosis (CF) [21]. This studymeets the criteria for a
well-conducted RCT. It has an appropriate design, randomization,
double blinding, placebo control and analysis by intention-to-treat
(ITT) [21].
The validity of RCTs is built around precise requisites (Table 1),
starting from a careful and rigorous experimental plan. Scientists
must establish the aim, the primary and secondary outcomes, size Randomization
 Blinding
 Control
 Rigorous analysis methods
inhaler techniques
 Realistic therapy
adherence
 Logistical and ethical
feasibility
 Able to evaluate
complex therapies
 Useful to detect rare
or late side effect
 Routine practice setting
 Long duration
Disadvantages  Selected patients
 Setting and monitoring bias
 Economical limitations
 Logistical and ethical
restrictions
 Unsuitable for complex
treatments studies
 Inappropriate for thorough
evaluation of side effects
 Short duration
 Lack of patient selection
brings confounding factors
 Lack of randomization
 Absence of blinding
 Residual monitoring bias
 Confounding by indication
 Economical limitations
 Logistical problems
 Immortality bias
Table 1 describes the main advantages and disadvantages of both RCTs and real life
studies. Advantages and disadvantages of RCTs are associated to their strict design
and population selection, which make their conclusion robust but distant from real
life conditions. On the other side, real life studies reﬂect more closely related to
usual care, but they provide results obtained in sub-optimal treatment conditions.
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method, the control, the analysis method and all other phases or
components of the trial [2].
The randomization process by which patients are allocated to
treatment groups is a key element of RCT design. It guarantees that
the groups are equal and comparable in all known and unknown
characteristics that could potentially inﬂuence outcomes [2,12].
With this type of distribution, the groups differ only in their
exposure to the treatment investigated [22]. This procedure avoids
selection bias since every person has the same probability of
receiving the test treatment(s) or the control [12].
In addition to randomization, also blinding reduces the possi-
bility of bias. In a well-designed RCT, people directly involved in the
study do not know how patients were allocated to treatments [23].
This avoids confounding factors linked to subjective perception of
therapeutic effects because patients and health-care providers
managing the therapy administration are unaware of the treatment
assigned. Blinding of outcome assessors increases the reliability of
the results because it assures the same interest and attention to
each patient and to every result, minimizing also detection bias, i.e.
systematic errors linked to evaluation of the results [23,24]. A
distinctive feature of RCTs is the presence of a control for compar-
ison. With proper controls, an RCT can provide a relative evaluation
of efﬁcacy, increasing the consistency of the conclusions. Controls
for comparison allow a more objective evaluation of the effect and
increase the robustness of the study design.
RCTs require an analytical approach to data analysis, to avoid
methodical systematic bias. This is typically obtained by using ITT
analysis [23,25], one of the strongest methods to prevent analytical
bias [13,23].
ITT analysis considers that all patients belong to the groups to
which they were initially randomly assigned, even if they subse-
quently withdraw or move/switch to another treatment group.
Patients who do not receive the assigned treatment should not be
excluded from the planned analysis since they usually do not have
the same prognostic features as the others [23].
2.3. RCTs: limitations
Even the best RCT has limitations, because its well-deﬁned
structure implies some artifacts. Indeed, although RCTs are
precious tools to assess treatment efﬁcacy, their applicability is
restricted to ideal conditions and this limits their ability to portray
what happens in the real world [7,14,26e29] (Table 1).
One of the more relevant limitations of RCTs is a direct conse-
quence of rigorous patient selection based on selective inclusion
and exclusion criteria [7]. The reason behind such selective
enrollment is to minimize the presence of confounding factors [7].
Thus, a “trial” population is selected and differs from the general
population [30]. A Norwegian study recently evaluated the
magnitude of this difference by assessing the actual population
referred to an asthma clinic using the inclusion and exclusion
criteria commonly adopted in RCTs in asthma (e.g. non-smokers
with a deﬁned range of airﬂow obstruction and no comorbidities,
1e2 exacerbation in the previous 12 months but none in the last
month, symptomatic or not when treated with speciﬁed doses/
types of medication). They found that less than 3% of the real
population would be eligible for randomization. This is clearly not
representative of the asthma population attending an asthma clinic
in real life [31]. A similar study reported that less than 20% of pa-
tients with COPD meet the usual enrollment criteria for RCTs in
COPD [31]. More recently, it has been conﬁrmed that, by applying
the commonly adopted inclusion/exclusion criteria to a large pop-
ulation of individuals with an established diagnosis of COPD, less
than one out of ﬁve patients would be eligible for the RCTs [32].Consequently, RCTs do not consider a number of factors that
potentially inﬂuence outcomes in real life [14,33e37]. In particular,
tobacco smoking, concomitant diseases, adherence to treatment
should be considered because it affects responsiveness to cortico-
steroids [29,38,39], the ﬁrst choice treatment for asthma.
Interestingly, the majority of asthma trials do not accept cur-
rent/former smokers, while the majority of COPD trials exclude
asthmatics, so there are no data on the large subgroup of patients
(w30%) who have poor lung function and unfavorable clinical
outcomes (e.g. frequent hospitalizations) [29,40e43].
Elderly asthmatic patients are another group traditionally
excluded from RCTs, even though this clinically relevant population
experiences high rates of hospitalization and asthma related death
[29,44,45]. Excluding such patients and, for example those with
comorbidities, results in a lack of treatment solutions in exactly the
groups where they could have high clinical impact [29,46].
In clinical practice comorbidities are frequently encountered in
patients with obstructive lung diseases. They are reported in more
30% of asthmatic patients and in the majority (>60%) of COPD pa-
tients [31]. Concomitant diseases can affect the clinical manifesta-
tion of respiratory disorders (e.g. increasing risk of COPD
exacerbations) [47,48] and their responsiveness to treatments (e.g.
depression or other psychological problems reduce adherence to
therapy, and obesity is associated to a lower response to inhaled
corticosteroids) [49,50]. In addition, the presence of comorbidities
can inﬂuence the pharmacological approach to obstructive lung
diseases, e.g. the use of b2-agonists and of b blockers in patients
with obstructive lung diseases and concomitant heart problems
[48,51,52]. In general, the interplay between concomitant diseases/
treatments cannot be properly assessed in RCTs.
On the other side, strict selection might focus only on patients
who will respond better to the tested treatment leading to over-
estimation of treatment effects [53]. Patients included in RCTs are
usually adept at inhalation techniques: they are instructed on the
use of inhalers and frequently monitored. Adherence to treatment
is usually high in RCTs as this is a prerequisite for randomization,
assessed during run-in: a sort of pre-selection of the population
that can maximize treatment effects [14]. Clearly, this does not
reﬂect everyday clinical practice, largely characterized by poor
inhaler technique and low treatment observance [7,14,54]. In
addition, subjects participating in RCTs are more likely to follow
instructions [22,55]. Subjects enrolled in studies tend to pay closer
attention to their health. This may minimizing any further advan-
tages from the trial intervention and result in underestimation of
preventive effects [22,55,56].
Interestingly, differences in patient selection criteria between
RCTs may produce conﬂicting results for a given outcome [10,57].
For instance, there are contradictory data on the protective efﬁcacy
of bacillus CalmetteeGuérin vaccine in the prevention of tubercu-
losis, probably linked to various diagnostic criteria used in different
settings [10,58,59].
In addition to selection bias, RCTs have also a monitoring bias
linked to the higher frequency of assessments and visits, compared
to clinical practice [13]. The awareness of being monitored can in-
ﬂuence outcomes by improving performance and reducing dis-
similarities between different therapies. In addition, placebo effect
may reduce the difference between active and control treatment,
not only on subjective but also on objective measurements [14,60e
62].
Another possible bias of RCTs derives from the clinical setting of
the trial. Often the patient population is followed in specialized
centers, where the available specialists and technologies differ from
those in most general practice settings [11]. Thus, patient man-
agement in RCTs is not representative of usual care [11]. In addition,
at variance with daily practice [63], RCTs usually comply with
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and treatment appropriateness.
RCTs have economical, logistical and ethical restrictions that can
make them inappropriate for analyzing issues related to public
health systems or unsuitable for speciﬁc conditions. For example,
their design cannot be applied when evaluating rare conditions.
Similarly, they cannot be utilized when the study concerns the cost,
convenience, or safety of a therapy, but not its efﬁcacy [2]. More-
over, RCTs do not take into account that each treatment becomes
part of the complex health care system. This can potentially inﬂu-
ence the use of the medication in daily practice in different ways,
including accessibility and price/reimbursement, which often differ
by country [2].
Because of feasibility limitations, RCTs usually assess a single
distinct intervention in a speciﬁc setting. They have limited possi-
bility to investigate the complex treatments common in real life,
especially in the elderly and polymorbid populations [2,5]. For these
reasons, the strict design of RCTs does not allow full detection of the
side effects or complications associated with an intervention,
particularly if these result from pharmacological interactions or
concomitant comorbidities, or if they have a delayed onset [1,2,5,6].
Timing is another constraint with RCTs, which frequently have
duration of weeks or few months [7,14,64e66]. Such a timeframe
minimizes problems with management, costs, and patient with-
draws [7,64e66], but is signiﬁcantly shorter than the usual treatment
period for chronic respiratory diseases [13]. This limits their ability to
provide reliable information on long-term treatment [2,14].
In summary, there is an urgent need for clinical information
beyond that obtainable from classical RCTs. Recent concerns have
been raised regarding the safety of the patients enrolled in RCT and
exposed to a standard (not tailored) and unknown (double blinded)
care [67]. Thus, it is not surprising that, in the past ten years, there
has been an impressive increase in the number of the real life
studies in asthma and COPD [68e75].
3. Real life studies
3.1. Real life studies: deﬁnition and features
Real life studies have been described in a variety of ways. The
EuropeanWorking Group on Relative Effectiveness has deﬁned real
life trials as a way to analyze medical data collected under real life
conditions [27]. In essence, they are conducted in everyday settings,
and for this reason, they provide insights into the real life effec-
tiveness of a medical condition/intervention.
They can be observational or descriptive, i.e. non-interventional,
or they can evaluate therapeutic interventions in usual care settings
[27]. Numerous strategies have been described for collecting data to
inform real world clinical decisions. Examples include databases,
patient and population surveys, chart reviews, registries,Table 2
Types of real life studies.
Type Characteristics
Databases  Cross-sectional or longitudinal analysis of
previously collected data.
Population surveys  Surveys, patient health status and opinion assessmen
Patient chart reviews  In depth evaluation of previously collected data, part
focusing on diagnosis and treatment.
Registries  A medical institute record of all patients treated for a
speciﬁc disease.
Observational data  Prospective or retrospective data collection, usually o
population cohorts, over a long follow-up period.
Pragmatic trials  Assesses treatment outcomes in the context of real-li
clinical practice.
This table describes the main types of real life studies, their features, including the sourobservational studies and pragmatic clinical trials (Table 2) [27].
However, observational and pragmatic trials are the most widely
used.
Observational studies are designed to monitor and describe real
life management/treatment of clinical conditions, without inter-
ference from the strict rules that limit the generalizability of RCTs.
They can be both prospective and retrospective and consist of
cohort, caseecontrol and cross-sectional studies [14]. By nature,
they can assess large populations over long follow-up periods.
Pragmatic clinical trials are the type of real life studies closest to
RCTs: they compare treatments/clinical interventions. At variance
with RCTs, pragmatic trials are conducted in a routine care setting
with heterogeneous patient populations and prolonged durations,
which increase the likelihood of obtaining conclusions relevant to
clinical practice [14,30,76e78].
The reliability and feasibility of analyzing data from real life
sources are debated because of the variable quality of data from
primary (medical records) or secondary (healthcare databases)
sources [10,79]. For example, in different hospital databases the
same pathological condition may be registered under different
names (e.g. pulmonary ﬁbrosis or interstitial lung disease) and this
could inﬂuence subsequent data analysis. Whereas a single source
usually registers such data under the same category; however, this
means that any mistakes in diagnosis/management are repeated
for all cases. Currently, there is no consensus on the best way to
collect such data, but comparing the information obtained from
various types of registries seems reasonable. When lung function
data are available the risk of under/misdiagnosing obstructive lung
diseases is reduced [80].
3.2. Real life studies: advantages
Real life studies reﬂect how treatments/interventions are
administered in everyday clinical practice (Table 1). At variance to
RCT, real life studies in asthma involve a heterogeneous non-
selected population that includes smokers, all level of disease
severity, atypical patients, patients with comorbidities, and those
with low adherence and poor inhaler handling or inhalation tech-
nique [81,82]. This insures that every subject who potentially will
receive the test treatment is represented in the study [81] Real life
studies do not use inclusion and exclusion criteria: being non-
selective they can include all the variables that can inﬂuence out-
comes under real life conditions. This qualifying characteristic may
lead to discrepancies with the results obtained by RCTs for a given
outcome. Such is the case for asthma control, which is attained in a
large proportion patients in RCTs, but not in real life conditions
[7,83]. This may be due to differences in education on inhaler
handling and in the choice of the most suitable inhaler for each
patient [14,84]. RCTs and guidelines do not ascribe differences in
clinical outcomes to inhalers [14,17,19,85e87], possibly becauseApplication
 Retrospective data analysis on various topics.
t.  Epidemiological studies.
icularly  Assessment of disease management for planning guidelines.
 Analysis of a medical centre experience/management/changes
in the treatment of a disease.
n  Examination of medical intervention effectiveness, including
safety and tolerability.
fe  Compare interventions under routine clinical circumstances.
ce of data, and their applications in effectiveness studies.
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devices [14,88]. Conversely, differences emerge from real life
studies, particularly in asthma, one of the ﬁrst clinical conditions in
which inhaler technique was investigated. An observational study
revealed that using the same type of inhaler device for mainte-
nance and rescue medication improved clinical results [89]. A
cohort study demonstrated that monotherapy with inhaled corti-
costeroids (ICS) is more successful when patients use breath-
actuated pressurized metered dose inhalers (BA-pMDIs) or dry
powder inhalers (DPIs) rather than pressurized metered dose in-
halers (pMDIs) [90]. Interestingly, the opposite was found for
combination therapy ICSþ long acting beta2 agonist (LABA), where
a cohort study reported that a pMDI formulation of ﬂuticasonee
salmeterol provides greater beneﬁts than a DPIs formulation [91];
moreover, a cross-sectional trial demonstrated that an extraﬁne
formulation of beclomethasoneeformoterol combination pMDI
leads to better asthma control than ICS/LABA formulations DPIs
[92]. These apparently conﬂicting results require careful interpre-
tation but they underscore the importance of device selection and
show how it can potentially inﬂuence clinical outcomes in real life.
Adherence to inhaled treatment is a major issue in routine
practice and may represent another factor responsible for the dif-
ference between the results from RCTs and real life studies. In a
recent survey, 18% of patients with chronic respiratory disorders
reported discontinuation of the prescribed inhaled treatment
because the difﬁculties in using the inhalers [93]. Several real life
studies have assessed adherence to asthma medication with
different formulations and treatment regimens. One study
compared adherence rates to once-daily versus twice-daily
mometasone furoate and found that the once-daily regimen is
associated with better compliance [94]. Moreover, this study
included non-adherent patients in the ﬁnal analysis, thus providing
valuable information for real life practice [94]. Evidence of how real
life variables can subvert the ideal conclusions from RCTs was
provided in a study on the efﬁcacy of leukotriene receptor antag-
onists (LTRAs), a second line treatment for asthma in adults in RCT
settings [95]. This study was a multicenter pragmatic trial that
compared the real world effectiveness of 1) LTRA with low dose
inhaled glucocorticoid as ﬁrst-line asthma-controller therapy, and
of 2) LTRA with LABA as add-on therapy in patients not controlled
by low dose ICS [95]. The treatments were proven to be equivalent
for asthma control, with a greater compliance to oral treatment
compared to inhaled treatment, which contribute tomake a second
line oral treatment (LTRA) appear as effective as ﬁrst choice inhaled
treatment [95]. This was conﬁrmed in children, where adherence to
monotherapy with LTRAwas better than to that of ICS [96]. Thus, in
real life, higher adherence to an oral medication compared to an
inhaled medication (ICS) may overturn the conclusions on efﬁcacy
obtained in RCTs [14,95,96].
Real life studies are immune to the logistical and ethical con-
straints that limit the feasibility of RCTs. The absence of these lim-
itations endows observational studies with the power to assess
outcomes such as hospitalization and mortality [16], and enables
pragmatic trials to estimate cost-effectiveness under real life con-
ditions [7,28]. Comparing the results fromobservational trials versus
RCTs on these issues reveals that estimates of cost-effectiveness
based on RCTs lack external validity [97], while real life studies are
more reliable as they reﬂect everyday clinical practice [28].
The characteristics of real life studies make them useful tools for
evaluating complex therapies, and policies for prescribing and
management [76,98]. An observational study in patients experi-
encing an acute asthma attack reported on prescribing patterns
before accessing the emergency department [99]. This analysis
determined that a lack or delay in medical intervention substan-
tially affected the level of optimal asthma management. Suchinformation cannot be obtained from RCTs, where the disease
management plan is pre-deﬁned, including emergencies events,
without variability in the treatment or timing of interventions
[7,100]. In addition, at variance with RCTs, which usually compare
treatments and placebo, real life studies are able to integrate
alternative health care options, providing information on the
management of complex interventions, which are very common in
the routine health care setting and inﬂuence the clinical decision
process [76]. A typical example is represented by the potential
cardiovascular effects of bronchodilators in patients with cardio-
vascular comorbidities that are excluded from the majority of RCTs.
The nature and characteristics of real life studies make them the
appropriate setting to assess safety. Their large scale and long
duration in non-selected populations favor the identiﬁcation of rare
complications or interactions with other treatments.
An additional advantage of real life studies is their natural
practice setting, e.g. physicians’ ofﬁces or clinics, which ensures
that they have external validity [76]. Involvement of patients from
different settings increases the variability of the results, but also
reproduces the complexity of the health care system more reliably
than the controlled conditions in RCTs [76].
Finally, real life studies have the beneﬁt of longer durations than
RCTs. This timing permits a more appropriate assessment of the
long-term effects of medical interventions, and the identiﬁcation of
late side effects, by following the natural course of a disease [76].
Thus, real life studies have many positive features and play a key
role in the investigation of clinical conditions and interventional
opportunities. These intrinsic values explain the increasing
importance of such studies in clinical research.
3.3. Real life studies: limitations
The limitations of real life studies are often intrinsically associ-
ated with their characteristic design (Table 1). The proximity to the
real world, with all its complexity, including different disease
manifestations, comorbidities, variable treatment adherence, sub-
optimal inhaler technique and multiple therapies, often dilutes the
magnitude of a treatment effect [7].
The lack of patient selection, one of the most distinctive char-
acteristics of real life studies, makes it impossible to avoid unmea-
sured confounding factors [11,29], while the absence of blinding and
randomization does not always allow factors potentially inﬂuencing
the outcomes to be properly balanced [14,53,101]. This is particularly
true in studies with subjective outcomes, which can be inﬂuenced
even by the patient’s awareness of the treatment they are assigned
to [24,30]. However, this “knowledge effect” can be interpreted as a
component of the treatment response that is normally present in
clinical practice. Thus, it can be compared to a “placebo effect” and
the difference between the overall treatment effect observed
(including the knowledge effect) and the “placebo (knowledge)
effect” can provide a reliable estimate of effectiveness [3].
Another challenge for real life studies is monitoring. Although
real life studies are planned to avoid the strict monitoring of RCTs,
some conditions, such as pragmatic trials, require frequent mea-
surements and medical supervision [7,14,102e105]. This tight
assessment can result in patient responses that differ from those
attainable in routine clinical practice. Indeed, each extra visit
potentially increases the patient’s response to therapy [106,107].
Under real-life conditions, in the absence of randomization,
severity of the underlying disease inﬂuences treatment decisions
[108]. This results in “confounding by indication”, meaning that the
perception of a different prognosis leads the physician to preferen-
tially prescribe one of the available treatments. As a result, prog-
nostic factors are not equally distributed among the patients treated
with different therapies and the comparison is affected by disease
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tematically different from the other groups in terms of illness stage
[53]. In addition, it is common clinical practice to follow severe
patients more closely [108,109]. This difference in monitoring
inﬂuences the results of real life studies. Sometimes the disease per
se requires a speciﬁc medical intervention, so the disease, not its
severity, represents the “confounding by indication” factor. In this
case, the severity/prognosis is considered a subtype of “confounding
by indication” [110]. An interesting example of this type of bias
comes from pediatric studies suggesting that the development of
asthma in children <5 years old is associated with the use of anti-
biotics [111,112]. This association was identiﬁed when antibiotics are
prescribed for lower respiratory tract infections (LRTI) [113,114]. In
this case, the increased risk of asthma could be associated with LTRI,
rather than antibiotics. Indeed, children with severe LTRI requiring
antibiotics may be predisposed to developing asthma [115].
Economical and logistical demands pose an additional challenge
for real life studies. Indeed, long-term studies involving large
populations require considerable ﬁnancial resources [76] and are
logistically complex to manage. Long follow-up may represent a
barrier to patient retention over the entire study period. Moreover,
large populations are required to detect small treatment differences
or infrequent clinically events (e.g. rare side effects) [30].
Finally, in observational studies, the choice to treat is not strictly
regulated and can be made at any time during the disease history/
evolution. The results of observational studies showing that pre-
scription of ICS for COPD reduces the risk of subsequent hospitali-
zation and mortality were said to be affected by an “immortality
bias” [116]. In these studies, patients were considered to be
“exposed” to ICS, if it was prescribed within 90 days after hospital
discharge [116]. By deﬁnition, exposed patients could not incur re-
hospitalization or mortality (outcomes of the assessment) before
glucocorticoids were prescribed [117]. Thus, they were technically
outcome-free for up to 90 days, the so-called “immortal” follow-up
time. This potentially leads to overestimation of the effect of ICS on
these outcomes [16,117].
Therefore, it emerges that, although they reproduce real life
conditions, real life studies sometimes differ from authentic routine
clinical practice. Every artifact, large or small, potentially averts
from genuine results.
3.4. Real life studies: overcoming some of the limitations
Investigators have acknowledged the limitations of real life
studies and the search for solutions has begun (Table 3). A good
starting point for increasing reliability is to establish a study plan
with a critical design, a priori [7]. Given the importance of
balancing the variables among the groups assessed, even obser-
vational cohorts can be designed with eligibility criteria. Enrolling
patients with speciﬁc characteristics can improve the consistency
of the results [118].Table 3
Strategies for overcoming the limitations of real life studies.
Problem or limitation Solution purposes
 Lack of patient selection brings confounding factors
 Lack of randomization
A priori strict critica
 Absence of blinding
 Residual monitoring bias
Report the results in
following appropria
 Immortality bias Time-dependent an
 Confounding by indication Propensity score.
Table 3 describes the main limitations of real life studies and the recent purposed soluti
how some of these solutions derives from the analysis of RCTs strengths/advantages.The study report should be prepared following strict guidelines
that aim for the correct, accurate and reliable presentation of re-
sults [7,77,119]. For this purpose, the Consolidating Standards of
Reporting Trials (CONSORT) statement, initially created for the
standardization of RCTs [120], has been extended to cover also
pragmatic cluster trials, where randomization applies to groups
rather than individuals [121,122]. The CONSORT guide is a checklist
of items to incorporate in the study report in order to provide a
clear explanation of study procedures and analyses. This guide also
suggests that a ﬂow diagram be used to specify the role and posi-
tion of every subject involved in management of study [7,77].
Similarly, the Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE) statement is a systematic checklist of
items that deﬁne the characteristics of an observational study [119].
These tools for transparent reporting facilitate clear reporting of
data and help editors, reviewers and readers to critically evaluate
the aim and results of clinical studies [119].
Sources of bias linked to the timing of follow-up, such as the
“immortal period”, can be addressed by using a time-dependent
analysis that includes all treatments prescribed after enrollment,
and arranging follow-up using a time-varying approach [16]. This
more complete analysis permits a better understanding of temporal
dynamics [16].
The absence of randomization clearly limits the reliability of
conclusions from real life studies; however, differences between
groups can be minimized. One of the most effective methods to
control for equality between groups is propensity score matching
[123]. This analysis quantiﬁes the probability that a patient will
receive treatment, assigning a numerical value based on disease
severity, concomitant diseases, clinical history, prognostic param-
eters and other variables [124]. Subjects in different treatment
groups are thenmatched 1:1 for the same propensity score value to
neutralize imbalances between groups [102,125,126]. The analysis
may use propensity scores in a variety of way, for example for
stratifying and matching treated and untreated patients
[124,125,127e129]. Identifying the true confounding parameters
that should be included in the model represents a challenge and is
the object of debate [101]. Some relevant recommendations sug-
gest that the propensity scores should be based on all variables
potentially related to the outcome [129,130], or any variables linked
with treatment choice and results [123]. This method helps to
balance the occurrence of confounders between treated and un-
treated groups [101]. Propensity scores for studies on asthma
should be based on all the determinants of asthma control and
severity, the frequency of exacerbations and short acting beta2-
agonist use [14,131].
Regarding COPD, the most recent study to use propensity score
matching to counterbalance the absence of randomization and
potential confounding factors was the PATHOS trial. This Swedish
retrospective, observational study compared exacerbation rates
(deﬁned as hospitalizations, emergency visits and administration ofComplementarities by RCTs
l design.  Rigorous experimental design
 Randomization
 Blinding
a correct, accurate and reliable way
te statements.
 Rigorous analytical method
alysis.  Rigorous experimental design
 Rigorous analytical method
 Randomization
 Blinding
ons. It also underlines complementarity between real life studies and RCTs showing
S. Saturni et al. / Pulmonary Pharmacology & Therapeutics 27 (2014) 129e138 135oral steroids or antibiotics for COPD) in patients with moderate to
severe COPD who had been treated with either budesonide/for-
moterol or ﬂuticasone/salmeterol [132]. Information was collected
for more than 21,000 patients followed for up to 11 years from
primary care medical records and data from national hospital,
pharmacy and cause of death registries [132]. A propensity score
was calculated based on age, gender, lung function, number of
outpatient visits for acute exacerbations, number of prescriptions
for other medications, signiﬁcant comorbidities, and number of
previous hospitalizations [132]. A score between 0 and 1 was given
to each patient and a very tight matching was performed. Two
matched cohorts of 2734 patients each were identiﬁed, with a
follow-up comprising more than 19,000 patient-years. The study
reports that treatment with budesonide/formoterol signiﬁcantly
reduces the number of exacerbations and hospitalizations
compared to ﬂuticasone/salmeterol [132].
4. Conclusions
RCTs are essential research tools with strong internal validity
but low generalizability to real life conditions [7,14]. Thus, there is
an increased interest in real life studies because of their close as-
sociation with routine clinical practice [7]. Unfortunately, the main
limitation of these latter studies is the lack of internal validity.
RCTs and real life studies have opposite strengths, in terms of
validity. This has both negative and positive implications. On the
negative side, results obtained from only one type of study should
be interpreted cautiously [82]. On a positive note, these approaches
are complementary, so combining them increases their relative
value and helps overcoming their relative limitations. Comparing
effectiveness and efﬁcacy trials can provide important information,
even if they produce discordant results. This may indicate that the
intervention is appropriate under some conditions, but not others
[105]. On this basis, it is plausible to propose a workﬂow in which
results from RCTs need to be conﬁrmed by real life studies. As an
example, the results from a RCT in which a therapeutic option in
asthma is superior to the conventional treatment is then validated
in a larger real life setting.
It is important to recognize the characteristics of each type of
study and accentuate their strengths while attempting to address
their limitations through remedial strategies [30]. Propensity score
best represents this concept, increasing the reliability of the con-
clusions of observational studies where randomization cannot be
applied. Clinical research evolves also in the search of solutions to
its own limitations.
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